Now vaccines might be soon available at the regular market level. An expert government panel of India’s central drug authority granted regular market approval to COVID 19 vaccines Covishield and Covaxin. This means that the vaccine can be authorized to use without any conditions. The manufacturers of the 2 vaccines – Bharat Biotech and SII confirmed this development and said that this approval came from the SEC (Subject Expert Committee).
The CDSCO (Central Drugs Standard Control Organisation) announced the same on Twitter to confirm this development.
SEC of CDSCO has recommended for upgrade of covishield and covaxin status from restricted use in emergency situations to grant of new drug permission with conditions In adult population ,DCGI will evaluate the recommendations and give its decision.
— CDSCO_INDIA_INFO (@CDSCO_INDIA_INF) January 19, 2022Advertisement
“The Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) which reviewed SII and Bharat Biotech’s application for the second time on Wednesday has recommended granting regular market approval to Covishield and Covaxin subject to certain conditions,” an official source told news agency PTI said.
After being asked how the vaccines will be marketed, the source said that the vaccines will be available at all clinics and hospitals that are registered on CoWIN. At the time of administration, the clinic or hospital will have to put in details in CoWIN.
For more breaking news, click here.